Results of cytology and high‑risk human papillomavirus testing in females with cervical adenocarcinoma in situ

Andersson,Sonia; Mints,Miriam; Wilander,Erik

doi:10.3892/ol.2013.1350

Results of cytology and high‑risk human papillomavirus testing in females with cervical adenocarcinoma in situ

Authors:
- Sonia Andersson
- Miriam Mints
- Erik Wilander
View Affiliations

Affiliations: Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska University Hospital‑Solna, The Karolinska Institute, Stockholm S‑171 76, Sweden, Departments of Genetics and Pathology and Clinical Pathology and Cytology, Rudbeck Laboratory, Uppsala University Hospital and Uppsala University, Uppsala S‑751 85, Sweden
Published online on: May 15, 2013 https://doi.org/10.3892/ol.2013.1350
Pages: 215-219

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The incidence rates of cervical adenocarcinoma have been increasing over the last two decades, contrary to those of squamous cell carcinoma. This trend is particularly evident among females aged <40 years and has occurred despite extensive cytology‑based screening programs. The aim of the present retrospective database study was to investigate adenocarcinoma in situ (AIS) with respect to previous cytological results, high‑risk (HR) human papillomavirus (HPV) infections and histological results from AIS‑adjacent squamous mucosa. Databases were used to identify 32 female patients with AIS treated for various conditions between 2009 and 2012 at the Department of Gynecology, Uppsala University Hospital (Uppsala, Sweden) and previous cytological, HPV and histological results. Of the individuals in the study, 64.3% had a previously recorded cytological result showing squamous cell abnormalities; five had glandular cell abnormalities (18%) and two had AIS (7.1%). Among the patients with available HPV results, 95% were HR‑HPV‑positive; HPV18/45 predominated (77%), followed by HPV16 (27%). The patients with multiple HPV infections were aged ≤32 years, while patients aged ≥38 years were only infected with HPV18/45. All but three patients had cervical intraepithelial neoplasia (CIN) in the AIS‑adjacent squamous mucosa, 79% of which was CIN2 or worse. The present retrospective database study suggests that AIS is detected at screening mainly due to simultaneous squamous precursor lesions and that HPV18/45 infection is an increasing co‑factor for AIS in older patients. HPV analyses of glandular precursor lesions aid in the identification of female individuals at risk of progression to invasive disease, and thus have a favorable effect on adenocarcinoma prevention, together with vaccination.

View Figures

View References

1.	Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:153–156. 2001. View Article : Google Scholar : PubMed/NCBI
2.	International Collaboration of Epidemiological Studies of Cervical Cancer: Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 120:885–891. 2007. View Article : Google Scholar : PubMed/NCBI
3.	Clifford GM, Smith JS, Plummer M, Muñoz N and Franceschi S: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 88:63–73. 2003. View Article : Google Scholar : PubMed/NCBI
4.	Castellsagué X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, Meijer CJ and Bosch FX; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 98:303–315. 2006.PubMed/NCBI
5.	Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ and Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 189:12–19. 1999. View Article : Google Scholar : PubMed/NCBI
6.	Andersson S, Rylander E, Larsson B, Strand A, Silfversvärd C and Wilander E: The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer. 37:246–250. 2001. View Article : Google Scholar : PubMed/NCBI
7.	Gustafsson L, Pontén J, Zack M and Adami HO: International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control. 8:755–763. 1997. View Article : Google Scholar : PubMed/NCBI
8.	Vizcaino AP, Moreno V, Bosch FX, Muñoz N, Barros-Dios XM, Borras J and Parkin DM: International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer. 86:429–435. 2000. View Article : Google Scholar : PubMed/NCBI
9.	Visioli CB, Zappa M, Ciatto S, Iossa A and Crocetti E: Increasing trends of cervical adenocarcinoma incidence in Central Italy despite Extensive Screening Program, 1985–2000. Cancer Detect Prev. 28:461–464. 2004.PubMed/NCBI
10.	Bray F, Carstensen B, Møller H, Zappa M, Zakelj MP, Lawrence G, Hakama M and Weiderpass E: Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev. 14:2191–2199. 2005. View Article : Google Scholar : PubMed/NCBI
11.	Etherington IJ and Luesley DM: Adenocarcinoma in situ of the cervix - controversies in diagnosis and treatment. J Low Genit Tract Dis. 5:94–98. 2001.PubMed/NCBI
12.	Jaworski RC: Endocervical glandular dysplasia, adenocarcinoma in situ, and early invasive (microinvasive) adenocarcinoma of the uterine cervix. Semin Diagn Pathol. 7:190–204. 1990.PubMed/NCBI
13.	Andrae B, Kemetli L, Sparén P, Silfverdal L, Strander B, Ryd W, Dillner J and Törnberg S: Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst. 100:622–629. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Wright TC Jr, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, Hatch K, Noller KL, Roach N, Runowicz C and Saslow D: Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 103:304–309. 2004. View Article : Google Scholar
15.	Cuschieri KS and Cubie HA: The role of human papillomavirus testing in cervical screening. J Clin Virol. 32(Suppl 1): S34–S42. 2005. View Article : Google Scholar : PubMed/NCBI
16.	Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DA and Snijders PJ: Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 124:516–520. 2009.PubMed/NCBI
17.	Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C and Iftner T; Joint European Cohort Study: Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 337:a17542008. View Article : Google Scholar : PubMed/NCBI
18.	Dahlström LA, Ylitalo N, Sundström K, Palmgren J, Ploner A, Eloranta S, Sanjeevi CB, Andersson S, Rohan T, Dillner J, Adami HO and Sparén P: Prospective study of human papillomavirus and risk of cervical adenocarcinoma. Int J Cancer. 127:1923–1930. 2010.PubMed/NCBI
19.	Gyllensten U, Gustavsson I, Lindell M and Wilander E: Primary high-risk HPV screening for cervical cancer in post-menopausal women. Gynecol Oncol. 125:343–345. 2012. View Article : Google Scholar : PubMed/NCBI
20.	Sanner K, Wikström I, Strand A, Lindell M and Wilander E: Self-sampling of the vaginal fluid at home combined with high-risk HPV testing. Br J Cancer. 101:871–874. 2009. View Article : Google Scholar : PubMed/NCBI
21.	Richart RM: Cervical intraepithelial neoplasia. Pathol Annu. 8:301–328. 1973.PubMed/NCBI
22.	Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr and Young N; Forum Group Members; Bethesda 2001 Workshop: The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 287:2114–2119. 2002. View Article : Google Scholar : PubMed/NCBI
23.	Gustavsson I, Juko-Pecirep I, Backlund I, Wilander E and Gyllensten U: Comparison between the Hybrid Capture 2 and the hpVIR real-time PCR for detection of human papillomavirus in women with ASCUS or low grade dysplasia. J Clin Virol. 45:85–89. 2009. View Article : Google Scholar : PubMed/NCBI
24.	Gustavsson I, Lindell M, Wilander E, Strand A and Gyllensten U: Use of FTA card for dry collection, transportation and storage of cervical cell specimen to detect high-risk HPV. J Clin Virol. 46:112–116. 2009. View Article : Google Scholar : PubMed/NCBI
25.	Moberg M, Gustavsson I and Gyllensten U: Real-time PCR-based system for simultaneous quantification of human papillomavirus types associated with high risk of cervical cancer. J Clin Microbiol. 41:3221–3228. 2003. View Article : Google Scholar : PubMed/NCBI
26.	World Health Organization: International Statistical Classification of Diseases and Related Health Problems. 2010 Edition. World Health Organization; Geneva: 2011
27.	Plummer M, Schiffman M, Castle PE and Maucort-Boulch D: A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 195:1582–1589. 2007.
28.	Schiffman M, Castle PE, Jeronimo J, Rodriguez AC and Wacholder S: Human papillomavirus and cervical cancer. Lancet. 370:890–907. 2007. View Article : Google Scholar : PubMed/NCBI
29.	Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, Solomon D and Burk R; Proyecto Epidemiológico Guanacaste Group: Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 100:513–517. 2008. View Article : Google Scholar : PubMed/NCBI
30.	Castle PE, Rodríguez AC, Burk RD, Herrero R, Wacholder S, Alfaro M, Morales J, Guillen D, Sherman ME, Solomon D and Schiffman M; Proyecto Epidemiológico Guanacaste (PEG) Group: Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ. 339:b25692009. View Article : Google Scholar : PubMed/NCBI
31.	Herfs M, Yamamoto Y, Laury A, Wang X, Nucci MR, McLaughlin-Drubin ME, Münger K, Feldman S, McKeon FD, Xian W and Crum CP: A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci USA. 109:10516–10521. 2012. View Article : Google Scholar : PubMed/NCBI
32.	Tase T, Okagaki T, Clark BA, Twiggs LB, Ostrow RS and Faras AJ: Human papillomavirus DNA in glandular dysplasia and microglandular hyperplasia: presumed precursors of adenocarcinoma of the uterine cervix. Obstet Gynecol. 73:1005–1008. 1989.PubMed/NCBI
33.	Bergström R, Sparén P and Adami HO: Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer. 81:159–166. 1999.PubMed/NCBI
34.	Adegoke O, Kulasingam S and Virnig B: Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health (Larchmt). 21:1031–1037. 2012.PubMed/NCBI
35.	Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N and Cuzick J; New Technologies for Cervical Cancer screening (NTCC) Working Group: Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 11:249–257. 2010. View Article : Google Scholar
36.	Ashfag R, Gibbons D, Vela C, Saboorian MH and Iliya F: ThinPrep Pap Test. Accuracy for glandular disease Acta Cytol. 43:81–85. 1999. View Article : Google Scholar
37.	Pettersson BF, Andersson S, Hellman K and Hellström AC: Invasive carcinoma of the uterine cervix associated with pregnancy: 90 years of experience. Cancer. 116:2343–2349. 2010.PubMed/NCBI
38.	Gyllensten U, Lindell M, Gustafsson I and Wilander E: HPV test shows low sensitivity of Pap screen in older women. Lancet Oncol. 11:509–510. 2010. View Article : Google Scholar : PubMed/NCBI
39.	Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, Demuth F, Schiffman M, Wacholder S and Castle PE: Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 12:663–672. 2011. View Article : Google Scholar
40.	Saqi A, Gupta PK, Erroll M, Babiac A, Blackmun D, Mansukhani M and Vazquez M: High-risk human papillomavirus DNA testing: a marker for atypical glandular cells. Diagn Cytopathol. 34:235–239. 2006. View Article : Google Scholar : PubMed/NCBI